Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15412007 | 0.85 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL15411077 | 0.81 | PIK3CD (0.43) | PIK3CDPIK3CB | |
| SCHEMBL15410910 | 0.81 | PIK3CD (0.43) | PIK3CDPIK3CB | |
| SCHEMBL15412031 | 0.81 | PIK3CD (0.43) | PIK3CDPIK3CB | |
| SCHEMBL15411665 | 0.81 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL15410685 | 0.81 | PIK3CD (0.42) | PIK3CD | |
| SCHEMBL15411797 | 0.79 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL16874996 | 0.77 | PIK3CD (0.43) | PIK3CDPIK3CB | |
| SCHEMBL16874994 | 0.77 | PIK3CD (0.43) | PIK3CDPIK3CB | |
| SCHEMBL16875056 | 0.77 | PIK3CD (0.39) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | Takeda Califomia, Inc. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | Takeda Califomia, Inc. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | Takeda Califomia, Inc. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8835420-B2 | Azaindole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-8835420-B2 | Azaindole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-8835420-B2 | Azaindole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| WO-2014011568-A1 | AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | PIK3R5, PIK3R1, PIK3R2 | PIK3CD 6/4885PIK3CB 13/4885 |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | PIK3R5, PIK3R1, PIK3R2 | PIK3CD 6/4885PIK3CB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.